Brimonidine tartrate ( DrugBank: Brimonidine )

2 diseases

ID	Disease name (Link within this page)	Number of trials
13	Multiple sclerosis/Neuromyelitis optica	1
90	Retinitis pigmentosa	3

13. Multiple sclerosis/Neuromyelitis optica

Clinical trials : 3,340 / Drugs : 2,163 - (DrugBank : 383) / Drug target genes : 241 - Drug target pathways : 238

diseases per page:

Showing 1 to 1 of 1 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT02568111 (ClinicalTrials.gov)	February 2016	1/10/2015	Brimonidine Tartrate for the Treatment of Injection Related Erythema	Brimonidine Tartratefor the Treatment of Injection Related Erythema Associated With Sub-cutaneous Ad ...	Relapsing-Remitting Multiple Sclerosis (RRMS)	Drug: peginterferon beta-1a;Drug: brimonidine tartrate;Drug: Vehicle Gel	Biogen	NULL	Withdrawn	18 Years	N/A	Both	0	Phase 4	NULL

First Previous1Next Last

90. Retinitis pigmentosa

Clinical trials : 147 / Drugs : 176 - (DrugBank : 43) / Drug target genes : 49 - Drug target pathways : 110

diseases per page:

Showing 1 to 3 of 3 diseases

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	EUCTR2010-019079-32-PT (EUCTR)	19/05/2010	05/04/2010	A Multicenter, Patient-Masked, Safety Extension Study to Evaluate the Biodegradation of the Brimonid ...	A Multicenter, Patient-Masked, Safety Extension Study to Evaluate the Biodegradation of the Brimonid ...	Patients who participated in a previous intravitreal Brimo PS DDS study, including 190342-028D (Reti ...	Product Name: Brimonidine TartratePosterior Segment Drug Delivery System (Brimo PS DDS) Applicator S ...	Allergan Limited	NULL	Not Recruiting			Female: yes Male: yes	290		Portugal;Czech Republic;Germany;Italy;United Kingdom
2	EUCTR2010-019079-32-DE (EUCTR)	12/05/2010	13/04/2010	A Multicenter, Patient-Masked, Safety Extension Study to Evaluate the Biodegradation of the Brimonid ...	A Multicenter, Patient-Masked, Safety Extension Study to Evaluate the Biodegradation of the Brimonid ...	Patients who participated in a previous intravitreal Brimo PS DDS study, including 190342-028D (Reti ...	Product Name: Brimonidine TartratePosterior Segment Drug Delivery System (Brimo PS DDS) Applicator S ...	Allergan Limited	NULL	Not Recruiting			Female: yes Male: yes	290		Portugal;Czech Republic;Germany;Italy;United Kingdom
3	NCT00661479 (ClinicalTrials.gov)	July 2008	29/10/2007	An Exploratory Study to Evaluate the Safety of Brimonidine Intravitreal Implant in Patients With Ret ...		Retinitis Pigmentosa	Drug: 400 µg Brimonidine TartrateImplant;Drug: 200 µg Brimonidine TartrateImplant;Drug: 100 µg Brimo ...	Allergan	NULL	Completed	18 Years	N/A	All	21	Phase 1/Phase 2	United States;France;Germany;Portugal

First Previous1Next Last